Fosamax Osteonecrosis of the Jaw Settlement: Criteria Explained

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Science to Specific Drug Risk

The legacy of general health and science communication has long emphasized broad preventive measures and population-level outcomes, as exemplified by large-scale randomized trials examining interventions like low-dose aspirin in older adults with cardiovascular risk factors. These studies, while valuable for public health guidance, often operate at a distance from the specific exposures and adverse events that may arise in more targeted contexts. As the focus narrows from general preventive strategies to particular pharmaceutical agents, a critical pivot emerges: the need to understand how widely prescribed medications can, under certain conditions, lead to serious unintended consequences. This transition is especially relevant when considering bisphosphonate therapies such as Fosamax, which have been associated with osteonecrosis of the jaw—a condition that, while rare, carries significant morbidity. The shift from general health information to occupational exposure concern requires careful attention to the populations most at risk, including those with prolonged or high-dose exposure. In this context, the settlement criteria for Fosamax-related osteonecrosis of the jaw represent a legal and medical framework designed to address claims arising from such exposure, moving the discussion from broad health education to specific, actionable risk assessment.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication prescribed for the treatment of osteoporosis. A known but rare adverse effect associated with its use is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. This section outlines the clinical presentation, pharmacological context, mechanistic pathways, and risk considerations relevant to patients and settlement criteria. **Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw** Osteonecrosis of the jaw presents as exposed bone in the oral cavity that persists for more than eight weeks despite appropriate management. The condition is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is primarily clinical, based on visual examination and patient history. Imaging studies may be used to assess the extent of bone involvement. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, though a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Pharmacology and Reported Adverse Effects

Fosamax (alendronate) belongs to the bisphosphonate class of drugs, which inhibit bone resorption by osteoclasts. While effective in reducing fracture risk in osteoporosis, bisphosphonates have been associated with ONJ. In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as jaw pain or exposed bone were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, post-marketing surveillance has identified ONJ as a rare but serious adverse event. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to ONJ

The precise mechanism by which bisphosphonates contribute to ONJ is not fully understood, but several pathways have been proposed. Bisphosphonates suppress bone turnover by inhibiting osteoclast activity, which may impair the normal repair and remodeling of jawbone. A multiscale characterization of jawbone in estrogen-deficient rats treated with alendronate found that most jawbone characteristics were not significantly different from those of sham-operated controls (https://pubmed.ncbi.nlm.nih.gov/40345077/). The surface of alveolar bone surrounding teeth showed a trend of more erosion and addition of new bone tissues in ovariectomized rat groups compared to sham groups, but treatments using alendronate did not substantially change those characteristics (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings suggest that the jawbone may respond differently to bisphosphonates than other skeletal sites, such as the lumbar vertebrae, which showed significant bone alteration by ovariectomy and treatments (https://pubmed.ncbi.nlm.nih.gov/40345077/). The current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Adequacy of Warnings and Settlement Criteria

The prescribing information for Fosamax includes a warning under Section 5.4 that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning notes that ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of these warnings is a key consideration in litigation, as plaintiffs may argue that the risks were not sufficiently communicated to patients and healthcare providers. Settlement criteria for Fosamax-related ONJ claims typically require evidence of a diagnosis of ONJ confirmed by a healthcare provider, a history of Fosamax use, and a temporal relationship between drug exposure and the onset of symptoms. The timeline between exposure and documented harm can vary, with symptoms appearing from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients must also demonstrate that they experienced harm, such as pain, infection, or the need for surgical intervention. The presence of known risk factors, such as invasive dental procedures or concomitant therapies, may affect the strength of a claim. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), which may be relevant to mitigation of damages.

Timeline Between Exposure and Documented Harm

The onset of ONJ symptoms after starting Fosamax is variable, ranging from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Documenting the timeline of Fosamax use, dental procedures, and symptom onset is critical for establishing causation in settlement claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it related to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis. A rare but serious side effect is osteonecrosis of the jaw (ONJ), where bone in the jaw becomes exposed and fails to heal. This condition is associated with tooth extraction, infection, and other risk factors.

What are the settlement criteria for Fosamax-related ONJ claims?

Settlement criteria typically require a confirmed diagnosis of ONJ by a healthcare provider, documented history of Fosamax use, and a temporal relationship between drug exposure and symptom onset. Patients must also demonstrate harm such as pain, infection, or need for surgery.

How long does it take for ONJ symptoms to appear after starting Fosamax?

The onset of ONJ symptoms can vary from one day to several months after starting Fosamax. Most patients improve after discontinuing the drug, but symptoms may recur if rechallenged with the same or another bisphosphonate.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.